Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:17943963rdf:typepubmed:Citationlld:pubmed
pubmed-article:17943963lifeskim:mentionsumls-concept:C0040833lld:lifeskim
pubmed-article:17943963lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:17943963lifeskim:mentionsumls-concept:C0027819lld:lifeskim
pubmed-article:17943963lifeskim:mentionsumls-concept:C0035168lld:lifeskim
pubmed-article:17943963lifeskim:mentionsumls-concept:C0021270lld:lifeskim
pubmed-article:17943963lifeskim:mentionsumls-concept:C0392747lld:lifeskim
pubmed-article:17943963lifeskim:mentionsumls-concept:C1521798lld:lifeskim
pubmed-article:17943963pubmed:issue7 Suppllld:pubmed
pubmed-article:17943963pubmed:dateCreated2007-10-23lld:pubmed
pubmed-article:17943963pubmed:abstractTextNeuroblastoma is the most common malignancy in infants and 40% of neuroblastomas are diagnosed in the first year of life. While generally neuroblastoma behaves less aggressively in this age group, tumors that have adverse biologic characteristics do not differ in their behavior from counterparts in older children. Clinical and biologic behavior of neuroblastoma in children up to 460 days of age is similar to that in children less than 1 year of age. Thus the categorization of children up to 18 months of age into risk category is critically dependent on biologic characterization and assignment to appropriate treatment intensity categories.lld:pubmed
pubmed-article:17943963pubmed:languageenglld:pubmed
pubmed-article:17943963pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17943963pubmed:citationSubsetIMlld:pubmed
pubmed-article:17943963pubmed:statusMEDLINElld:pubmed
pubmed-article:17943963pubmed:monthDeclld:pubmed
pubmed-article:17943963pubmed:issn1545-5009lld:pubmed
pubmed-article:17943963pubmed:authorpubmed-author:CastleberryRo...lld:pubmed
pubmed-article:17943963pubmed:authorpubmed-author:FriedmanGrego...lld:pubmed
pubmed-article:17943963pubmed:copyrightInfoCopyright 2007 Wiley-Liss, Inc.lld:pubmed
pubmed-article:17943963pubmed:issnTypePrintlld:pubmed
pubmed-article:17943963pubmed:volume49lld:pubmed
pubmed-article:17943963pubmed:ownerNLMlld:pubmed
pubmed-article:17943963pubmed:authorsCompleteYlld:pubmed
pubmed-article:17943963pubmed:pagination1060-5lld:pubmed
pubmed-article:17943963pubmed:dateRevised2009-1-12lld:pubmed
pubmed-article:17943963pubmed:meshHeadingpubmed-meshheading:17943963...lld:pubmed
pubmed-article:17943963pubmed:meshHeadingpubmed-meshheading:17943963...lld:pubmed
pubmed-article:17943963pubmed:meshHeadingpubmed-meshheading:17943963...lld:pubmed
pubmed-article:17943963pubmed:meshHeadingpubmed-meshheading:17943963...lld:pubmed
pubmed-article:17943963pubmed:meshHeadingpubmed-meshheading:17943963...lld:pubmed
pubmed-article:17943963pubmed:meshHeadingpubmed-meshheading:17943963...lld:pubmed
pubmed-article:17943963pubmed:meshHeadingpubmed-meshheading:17943963...lld:pubmed
pubmed-article:17943963pubmed:meshHeadingpubmed-meshheading:17943963...lld:pubmed
pubmed-article:17943963pubmed:year2007lld:pubmed
pubmed-article:17943963pubmed:articleTitleChanging trends of research and treatment in infant neuroblastoma.lld:pubmed
pubmed-article:17943963pubmed:affiliationDepartment of Pediatrics, Division of Pediatric Hematology Oncology, University of Alabama at Birmingham, Birmingham, Alabama, USA. GFriedman@peds.uab.edulld:pubmed
pubmed-article:17943963pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:17943963pubmed:publicationTypeReviewlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17943963lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17943963lld:pubmed